Variables | nAMD (N=50) | DMO (N=37) | RVO (N=30) | P value* |
Baseline BCVA (ETDRS letters) | 55 (0–80) | 70 (0–80) | 55 (0–84) | 0.002† |
Baseline CMT (μm) | 353.5 (199–794) | 352 (276–987) | 483.5 (263–763) | 0.007‡ |
Lens status (% Pseudophakic) | 54 | 43 | 10 | <0.001§ |
Age (years) | 80 (61–98) | 71 (52–88) | 75 (45–90) | <0.001¶ |
Male (%) | 54 | 40 | 43 | 0.414 |
Laterality of eye (% R) | 54 | 57 | 33 | 0.115 |
Hypertension (% positive) | 64 | 92 | 73 | 0.011** |
Hyperlipidaemia (% positive) | 52 | 86 | 43 | <0.001†† |
Smoker (%) | 72 | 54 | 50 | 0.091 |
Injection type | ||||
Bevacizumab (%) | 38 | 54 | 57 | >0.05 |
Ranibizumab (%) | 8 | 3 | 13 | >0.05 |
Aflibercept (%) | 10 | 8 | 0 | >0.05 |
Mixed (%) | 44 | 35 | 30 | >0.05 |
Diabetes duration (years) | – | 23 (2–50) | – | – |
HbA1c (mg/dL) | – | 7.8 (5.9–12.1) | – | – |
Laser at baseline (% positive) | – | 57 | – | – |
Data are presented as medians (range) for continuous data and proportions for categorical data.
*P values are global p values testing for a difference between any of the diseases. (Kruskal-Wallis for continuous variables or χ2/Fisher’s exact for categorical). For comparisons that are significant at the global level, adjusted pairwise p values for individual study comparisons are reported. Significant p values are bolded.
†nAMD vs DMO p=0.002; DMO vs RVO p=0.020; nAMD vs RVO p=1.000.
‡nAMD vs DMO p=1.000; DMO vs RVO p=0.027; nAMD vs RVO p=0.008.
§nAMD vs DMO p>0.05; DMO vs RVO p<0.05; nAMD vs RVO p<0.05.
¶nAMD vs DMO p<0.001; DMO vs RVO p=0.858; nAMD vs RVO p=0.005.
**nAMD vs DMO p<0.05; DMO vs RVO p>0.05; nAMD vs RVO p>0.05.
††nAMD vs DMO p<0.05; DMO vs RVO p<0.05; nAMD vs RVO p>0.05.
BCVA, best-corrected visual acuity; CMT, central macular thickness; DMO, diabetic macular oedema; ETDRS, early treatment diabetic retinopathy study; Mixed, combination of either of the three injection types; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion.